Clinical profile and practice experience of almotriptan

Cephalalgia, Supplement

Volumn 24, Issue 2, 2004, Pages 16-23

  Gendolla, Astrid ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Almotriptan; Migraine; Pain free efficacy; Tolerability; Triptan

Indexed keywords

ALMOTRIPTAN; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SUMATRIPTAN; ZOLMITRIPTAN; FLUOXETINE; FROVATRIPTAN; KETOCONAZOLE; MOCLOBEMIDE; PLACEBO; PROPRANOLOL; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; VERAPAMIL;

ACUTE DISEASE; AGE; ASTHENIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; DIZZINESS; DRUG ABSORPTION; DRUG TOLERABILITY; FOOD INTAKE; HEADACHE; HEART PALPITATION; HUMAN; INCIDENCE; LUNG TOXICITY; META ANALYSIS; MIGRAINE; RECURRENCE RISK; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; THROAT DISEASE; ANALGESIA; ARTICLE; CHEST TIGHTNESS; CLINICAL EFFECTIVENESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG PROTEIN BINDING; PAIN INTENSITY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; QUALITY OF LIFE; THROAT TIGHTNESS; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT CONTRAINDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 10344256716     PISSN: 08001952     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2004.00894.x     Document Type: Conference Paper

References (42)

1. Gallagher KM. What do patients want from acute migraine treatment? Cephalagia 2004; 24 (Suppl. 2):8-15.
2. Davies GM, Santanello N, Lipton RB. Determinants of patient satisfaction with migraine therapy. Cephalalgia 2000; 20:554-60.
3. Lipton RB, Stewart WF. Acute migraine therapy: Do doctors understand what patients with migraine want from therapy? Headache 1999; 39 (Suppl. 2):S20-6.
4. Gallagher RM, Kunkel R. Migraine medication attributes important for patient compliance: concerns about side effects may delay treatment. Headache 2003; 43:36-43.
5. Silberstein SD for the US Headache Consortium. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. http://www.aan.com/professionals/prac tice/guidelines
6. Dodick DW. A review of the clinical efficacy and tolerability of almotriptan in acute migraine. Exp Opin Pharmacother 2003; 4:1157-63
7. Bou J, Domenech T, Puig J et al. Pharmacological characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. Eur J Pharmacol 2000; 410:33-41.
8. Bou J, Gras J, Cortijo J, Morcillo EJ, Llenas J, Palacios JM. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia 2001; 21:804-12.
9. Cabarrocas X, Salva M. Pharmacokinetics and metabolic data on almotriptan, a new antimigraine drug. Cephalalgia 1997; 17:421. (Abstract)
10. Boyce M, Dunn K, Warrington S. Hemodynamic and electroncardiographic effects of almotriptan in healthy volunteers. J Cardiovasc Pharmacol 2001; 37:280-9.
11. Dodick DW. Oral almotriptan in the treatment of migraine: safety and tolerability. Headache 2001; 41:449-55.
12. Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a two-year clinical practice review in 735 consecutive migraine patients. Cephalalgia 1996; 16:554-9.
13. Dahlöf CG, Dodick D, Dowson AJ, Pascual J. How does almotriptan compare with other triptans? A review of data from placebo-controlled clinical trials. Headache 2002; 42:99-113.
14. Jansat JM, Costa J, Salva P, Fernandez FJ, Martinez-Tobed A. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. J Clin Pharmacol 2002; 42:1303-10.
15. Cabarrocas X, Warrington SJ, Jansat JM, Zayas JM, Boyce M, Ferrer P. Pharmacokinetics and tolerability of oral almotriptan in the elderly. Cephalalgia 1999; 19:363. (Abstract)
16. Cabarrocas X, Jansat JM, Ferrer P, Luria X. Pharmacokinetics of oral almotriptan during end outside a migraine attack. Cephalalgia 2000; 20:417. (Abstract)
17. 1B/1D agonist, in healthy volunteers. Headache 1998; 38:376. (Abstract)
18. Jhee SS, Shiovitz T, Crawford AW, Cutler NR. Pharmacokinetics and pharmacodynamics of the triptan anti-migraine agents: a comparative review. Clin Pharmacokinetic 2001; 40 (3):189-205.
19. Anon. Almogran (almotriptan maleate) tablets. Summary of Product Characteristics. 2003.
20. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Pharmacokinetic interaction between verapamil and almotriptan in healthy volunteers. Clin Pharmacol Ther 2000; 67:498-503.
21. Fleishaker JC, Sisson TA, Carel BJ, Azie NE. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia 2001; 21:61-5.
22. Fleishaker JC, Ryan KK, Carel BJ, Azie NE. Evaluation of the potential pharmacokinetic interaction between almotriptan and fluoxetine in healthy volunteers. J Clin Pharmacol 2001; 41:217-23.
23. Fleishaker JC, Herman BD, Carel BJ, Azie NE. Interaction between ketoconazole and almotriptan in healthy volunteers. J Clin Pharmacol 2003; 43:423-7.
24. Von Seggern RL. Almotriptan: a review of pharmacology, clinical efficacy and tolerability. Am J Manag Care 2002; 8 (3 Suppl.):S74-9.
25. Cabarrocas X, Salvà M. Almotriptan has no pharmacokinetic/ pharmacodynamic interaction with ethanol. Cephalalgia 2002; 22:605. (Abstract)
26. Cabarrocas X, Macher JP. Lack of pharmacokinetic interaction between almotriptan and oral contraceptives: a double-blind, placebo-controlled, crossover study in healthy female volunteers. Cephalalgia 2003; 23:715. (Abstract)
27. Pascual J, Falk RM, Piessens F et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomized, double-blind, placebo-controlled study. Cephalalgia 2000; 20:588-96.
28. Mathew NT. Naratriptan: a review. Exp Opin Invest Drugs 1999; 8:687-95.
29. Dahlöf C, Tfelt-Hansen P, Massiou H, Fazekas A on behalf of The Almotriptan Study Group. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001; 57:1811-7.
30. Dowson AJ, Massiou H, Lainez JM, Cabarrocas X. Almotriptan is an effective and well-tolerated treatment for migraine pain: results of a randomized, double-blind, placebo-controlled clinical trial. Cephalalgia 2002; 22:453-61.
31. Martinez E, Cabarroccas X, Peris F, Ferrer P, Luria X. Meta-analysis of the efficacy and safety of almotriptan in the treatment of migraine. Cephalalgia 1999; 19:362. (Abstract)
32. 1B/1D agonists) in acute migraine treatment, a meta-analysis of 53 trials. Lancet 2001; 358:1668-75.
33. Pascual J, Falk R, Docekal R et al. Tolerability and efficacy of almotriptan in the long term treatment of migraine. Eur Neurol 2001; 45:206-13.
34. Diener HC, Landen H, Stauch K. Almotriptan in the treatment of acute migraine attacks: a post-marketing study in 899 patients. Nervenheilkunde 2003; 22:365-8.
35. Geraud G, Keywood C, Senard JM. Migraine headache recurrence, relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003; 43:376-88.
36. Tfelt-Hansen P, Block G, Dahlof C et al. International Headache Society Clinical Trials Subcommittee. Guidelines for Controlled Trials of Drugs in Migraine, 2nd edn. Cephalalgia 2000; 20:765-86.
37. Dodick DW. Almotriptan increases sustained pain-free outcomes in acute migraine: results from three controlled clinical trials. Headache 2002; 42:21-7.
38. Fernandez FJ, Jansat JM, Cabarrocas X, Costa J, Salva P. Absolute bioavailability of oral and subcutaneous almotriptan. Cephalalgia 1999; 19:363. (Abstract)
39. 1B/1D agonist, compared with sumatriptan 100 mg. Headache 1998; 38:377-8. (Abstract)
40. Lipton RB, Liberman J, Cutrer FM et al. Treatment preferences and the selection of acute migraine medications: results from a population-based survey. J Headache Pain 2004; 5:123-30.
41. Ferrari MD. TRIPSTAR: a comprehensive patient-based approach to compare triptans. Headache 2002; 42 (Suppl. 1):18-25.
42. Colman SS, Brod MI, Krishnamurthy A, Rowland CR, Jirgens KJ, Gomez-Mancilla B. Treatment satisfaction, functional status and health-related quality of life of migraine patients treated with almotriptan or sumatriptan. Clin Ther 2001; 23:127-45.